A Novel Source

Longboat Amniotics has identified a cell, originating from amniotic fluid, with properties ideal for regenerative medicine applications. We have developed a protected method and device for the extraction and use of this material.


We are currently developing infrastructure for distribution of the material for research and clinical use. This makes us aim for being a leading provider of stem cell therapeutics.


Perfect for Induced Pluripotent Stem Cells

We have identified the ideal starting cell for reprogramming applications and pluripotent stem cell based regenerative medicine. Our cells, with superior genomic integrity and epigenetic properties, possess qualities that we suggest will make iPS based regenerative medicine safer and have a greater likelihood for success.

Mesenchymal Stem Cells

Our technology will aim to provide an abundant source of mesenchymal stem cells (MSCs). The neonate origin of our cells we suggest endows them with more primitive properties, which are more suitable for today’s MSC based therapies. Access to amniotic fluid derived cells may also expand the use of MSC based cell therapies to additional diseases and therapeutic areas.

Endothelial Cells

Our unique separation method for isolation of endothelial cells from umbilical cord blood allows for the preservation of blood stem cell fraction while giving access to a therapeutically relevant cell type with properties suitable for both reprogramming based therapeutics and endothelial cell based cell therapies.

Additional Technologies

The method of collection of the stem cells also allows us to retrieve large quantities of a highly valuable human form of surfactant with properties we suggest are superior to current surfactant preparations. We have identified and patented the surfactant molecule and collection method to ensure the interface with air does not interfere with the active molecule.